Morgan Stanley analyst Drew Ranieri raised the firm’s price target on Intuitive Surgical to $330 from $300 and keeps an Equal Weight rating on the shares. A combination of rising 10 year rates and GLP-1 pressures have pushed the valuation of the U.S. MedTech sector down and given the material de-rating the firm is upgrading its Industry View on MedTech to Attractive, the analyst tells investors. Volumes remain in strong shape, capital equipment is looking healthy and the firm sees limited expected impact from GLP-1s, the analyst added in a note on the group in which the firm adjusted a number of price targets.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ISRG:
- Robotics Stocks: Bot is Man’s Best Friend
- Intuitive Surgical Stock (NYSE:ISRG): Waiting For a Discount Might be Futile
- These are the Stocks Most Negatively Correlated to Treasury Yields
- Intuitive Surgical (NASDAQ:ISRG) Gains after Analyst Approval
- Intuitive Surgical price target raised to $350 from $315 at Stifel